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Abstract
Background: Palivizumab, a monoclonal antibody and the only licensed immunization product 
for preventing respiratory syncytial virus (RSV) infection, is recommended for children with 
certain high-risk conditions. Other antibody products and maternal vaccines targeting young 
infants are in clinical development. Few studies have compared products closest to potential 
licensure and have primarily focused on the effects on hospitalizations only. Estimates of the 
impact of these products on medically-attended (MA) infections in a variety of healthcare settings 
are needed to assist with developing RSV immunization recommendations.
Methods: We developed a tool for practicing public health officials to estimate the impact of 
immunization strategies on RSV-associated MA lower respiratory tract infections (LRTIs) in 
various healthcare settings among infants <12 months. Users input RSV burden and seasonality 
and examine the influence of altering product efficacy and uptake assumptions. We used the tool 
to evaluate candidate products’ impacts among a US birth cohort.
Results: We estimated without immunization, 407,360 (range: 339,650–475,980) LRTIs are 
attended annually in outpatient clinics, 147,240 (126,070–168,510) in emergency departments 
(EDs), and 33,180 (24,760–42,900) in hospitals. A passive antibody candidate targeting all infants 
prevented the most LRTIs: 196,470 (48% of visits without immunization) outpatient clinic visits 
(range: 163,810–229,650), 75,250 (51%) EDs visits (64,430–86,090), and 18,140 (55%) 
hospitalizations (13,770–23,160). A strategy combining maternal vaccine candidate and 
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palivizumab prevented 58,210 (14% of visits without immunization) LRTIs in outpatient clinics 
(range: 48,520–67,970), 19,580 (13%) in EDs (16,760–22,400), and 8,190 (25%) hospitalizations 
(6,390–10,150).
Conclusions: Results underscore the potential for anticipated products to reduce serious RSV 
illness. Our tool (provided to readers) can be used by different jurisdictions and accept updated 
data. Results can aid economic evaluations and public health decision-making regarding RSV 
immunization products.
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1. Introduction
Globally, respiratory syncytial virus (RSV) is a leading cause of severe respiratory tract 
infections among young children. In 2015, there were an estimated 33.1 million acute lower 
respiratory tract infections, 3.2 million hospital admissions and 59,600 in-hospital deaths 
attributed to RSV infections (RSVi) among children < 5 years of age worldwide. About 45% 
of RSV-associated hospitalizations and deaths occurred among children <6 months of age 
[1]. Each year in the United States, ~1.5 million outpatient visits, ~500,000 emergency 
department (ED) visits, ~58,000 hospitalizations and ~150 deaths are associated with RSVi 
among children under 5 years of age [2,3]. Rates of medically-attended RSVi (MA-RSVi) in 
the United States are highest amongst infants < 6-months of age [4,5]. In the US and other 
temperate climates, RSV season generally lasts six months between fall and spring with a 
peak during the winter [6]. In countries with tropical or subtropical climates, the season may 
be longer and less predictable [7].
Palivizumab, currently the only licensed product to prevent RSVi, is recommended for use in 
children with certain “high risk” conditions [8]. It is given in monthly intramuscular 
injections during RSV season. There are over 40 vaccine and antibody products in 
development for prevention of RSVi [9]. Two products in late stages of clinical development 
target young infants: (1) a monoclonal antibody designed to provide direct protection 
(completed phase 2b clinical trial) [10]; and (2) a maternal vaccine designed to provide 
indirect protection through passive placental transfer of antibodies (completed phase 3 
clinical trial) [11]. Both of these products aim to protect against medically-attended lower 
respiratory tract infections (MA-LRTI) due to RSV. Additional maternal vaccines and 
antibody products are in the clinical development pipeline [9].
Previous studies have evaluated the potential impacts of immunization on MA-RSVi in a 
variety of countries [12–19]. These analyses have focused on the hospital setting and 
impacts from single, theoretical vaccine products. Only one (Cromer et al.) simultaneously 
compared multiple products in the later stages of clinical development and across several 
healthcare settings [13]. Cromer et al. estimated the direct effects of various pediatric and 
maternal immunization candidate products and strategies using a cohort model in England. 
While Cromer et al.’s model more closely matches trial endpoints for products potentially 
close to licensure, its assumptions may not be generalizable to populations that have 
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different rates of disease and seasonality. It also assumed the entire population eligible for an 
immunization product received it (i.e. 100% uptake), which likely overestimates the public 
response. The evolving state of product development highlights the need for flexible and 
accessible modeling tools, which can be readily updated to reflect advancements in our 
knowledge of product characteristics, and which can be applied to jurisdictions with varied 
RSV epidemiology.
We therefore developed a modeling tool, called the RSV Immunization Impact Model (RSV 
I2M), for use by practicing public health officials and policy-makers in their jurisdictions, to 
estimate the direct effects of immunization candidates targeting young infants, on MA-RSV-
associated LRTIs. RSV I2M evaluates the potential impact of these products on outpatient 
clinic visits, ED visits, and hospitalizations based on user-adjustable RSVi rates and 
seasonality, in conjunction with assumptions about product uptake and efficacy. Model 
outputs (visits with and without immunization for LRTI due to RSV) can assist policy-
makers in the United States and other countries with developing economic analyses and 
recommendations for RSV immunization. We also apply the model to a US birth cohort to 
estimate the potential impact of these products on MA-LRTI due to RSV in the United 
States.
2. Methods
2.1. Tool overview
RSV I2M is a spreadsheet-based tool (Supplementary Material [S1]) that uses a Decision 
Tree model to estimate the potential impact of three immunization strategies on MA-RSV-
associated LRTIs among an annual birth cohort through 12 months of age. The birth cohort 
is divided into “high-risk” and “low-risk” (all other) infants. High-risk infants include those 
with hemodynamically significant CHD, chronic lung disease of prematurity (CLDP), and 
infants born prematurely at <29 weeks gestational age based on recommendations for who 
should receive palivizumab prophylaxis [8]. The first strategy (Strategy I) generally follows 
current US-based recommendations that high-risk infants receive monthly injections of 
palivizumab during the RSV season (typically October to March) during their first year of 
life. [8] In the model, palivizumab is given starting at birth for those born during the season, 
and starting at the beginning of the next RSV season when births occur out-of-season (OoS) 
(Table 1). The second strategy (Strategy II) provides a new antibody product, hereafter 
referred to as the “Antibody Candidate” strategy, injected as a single dose with the same 
timing of palivizumab initiation, but targeting all infants rather than just those at high risk. 
The third strategy (Strategy III), the “Maternal Vaccine Candidate + Palivizumab” strategy, 
combines providing vaccine to mothers in their third trimester throughout the year (not just 
during the season) and palivizumab to high-risk births based on the palivizumab schedule 
described above.
Estimates of MA-RSVi visits without any immunization are based upon user inputs 
regarding the size of their birth cohort, prevalence and risk of RSV hospitalizations among 
those with high-risk conditions, rates of RSV (combined for high- and low-risk infants) by 
month of age in the outpatient clinic, ED, and hospital settings, the proportion of MA-RSVi 
visits resulting in a LRTI diagnosis, and RSV seasonality (Table 2). To estimate the effects 
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of immunization, users input immunization uptake, efficacy, and duration of protection for 
each product (Table 2). Uptake was defined as the proportion of the population expected to 
receive the products. Efficacy is defined as the percent protected assuming recipients receive 
the full immunization dose at the correct time. For the maternal vaccine, efficacy is reduced 
by assumptions about the proportion of antibodies that successfully transfer to the infant 
(based on the timing of the mother’s vaccination and the infant’s gestational age a birth; 
Table 2, Supplementary Material [S2]). Users can readily update a number of input values as 
new data become available or to reflect a jurisdiction’s immunization policy considerations. 
To illustrate the tool, we used it to estimate the effects of the aforementioned immunization 
strategies on a US birth cohort.
2.2. Calculations
2.2.1. Visits without immunization—To calculate the number of MA-RSVi resulting 
in LRTI for each of the three healthcare settings, we multiplied the “all-risk” (high-and low-
risk) MA-RSVi rate by the proportion of visits in each setting with an LRTI diagnosis and 
the size of monthly birth cohorts (assuming births occur evenly across the year) (S2). These 
results were then distributed to calendar months based on RSV seasonality by multiplying 
them by the percent of annual visits occurring in each month. For countries that currently 
use palivizumab, like the United States, we added to the monthly visit counts MA-LRTIs 
that would have occurred in the absence of palivizumab. For the hospital setting, these 
additional visits were determined by multiplying the rate of hospitalizations among high-risk 
infants by the size of the high-risk cohort, palivizumab uptake, and palivizumab efficacy. 
The hospitalization rates used in this calculation are a weighted average across the different 
high-risk groups (S2). For the outpatient clinic and ED settings, we assumed the ratio of 
rates between high- and low-risk infants is the same as the ratio of hospitalization rates for 
high and low risk infants, and that palivizumab would have the same efficacy for preventing 
cases in these settings (S2).
2.2.2. Visits prevented with immunization—To obtain the annual number of visits 
prevented with immunization for a given strategy and setting, we summed the visits 
prevented across all months that the immunization remained protective, based on its duration 
of protection. We calculated the monthly visits prevented with each immunization strategy 
differently. For Strategy I, LRTI visits prevented by palivizumab equaled the calculated 
number of MA-RSV-associated LRTIs without immunization among high-risk infants, 
multiplied by palivizumab uptake and efficacy. For Strategies II and III, visits prevented by 
the immunization candidates equaled the number of MA-RSV-associated LRTIs without 
immunization among both high- and low-risk infants, multiplied by the candidate uptake in 
each risk group and efficacy. The efficacies for both candidates assumes recipients receive 
the full immunization dose. To account for incomplete transfer of antibodies from mother to 
child for a portion of births, we multiplied the maternal vaccine efficacy in Strategy III by a 
reduction factor. This factor considers the delay in the mother’s production of antibodies 
after vaccination (dependent on the timing of vaccination relative to birth) and the fact that 
the amount of antibody transfer is dependent on gestational age at birth (S2). In Strategy III, 
high-risk infants are also eligible to receive palivizumab; therefore, we added the number of 
visits prevented by palivizumab when calculating the total annual prevented visits for this 
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strategy. Finally, we calculated the visits that would occur despite having each immunization 
strategy in place: this equaled visits without immunization minus visits prevented.
2.2.3. Deaths with and without immunization—Since data are sparse on the number 
of RSV-associated deaths that occur outside the hospital setting, we estimated deaths with 
and without immunization based on deaths among hospitalized infants. We calculated deaths 
without immunization by multiplying user-provided hospitalized case fatality ratios (hCFR) 
for infants 0–5 months of age and for those between 6 and 11 months of age and the total 
annual estimate for hospitalizations due to RSV-associated LRTIs without immunization for 
these age groups. Deaths prevented by immunization were calculated similarly to medically-
attended visits prevented, whereby deaths that occur without immunization were multiplied 
by the uptake and efficacy for each product. Finally, deaths that would occur despite having 
each immunization strategy in place equaled deaths without immunization minus deaths 
prevented through immunization.
2.3. Model inputs and sensitivity analysis
To illustrate the model, we estimated the impact of implementing the three immunization 
strategies in the United States. Table 2 includes all model inputs, values used and sources 
(with additional detail in S2).
We conducted two sensitivity analyses of immunization candidates’ impacts. In the first, we 
evaluated the influence of high and low estimates for individual parameters, while all other 
parameters were held constant. For this analysis we used the 95% CI bounds for MA-RSVi 
rates, five percentage point reductions and improvements in the baseline uptake for the 
antibody candidate (66–76%) and maternal vaccine candidate (51–61%), the 95% CI bounds 
for efficacy reported in clinical trial results for an antibody candidate (73–85%, which we 
assumed for the maternal vaccine candidate as well), and one month reductions and 
improvements in durations of the antibody candidate (120–180 days), and maternal vaccine 
candidate (60–120 days) (Table 2).
In our second sensitivity analysis, we examined the impact of uptake of the immunization 
candidates on LRTI visits by accounting simultaneously for uncertainty in RSV rates, 
uptake, efficacy, and duration. We present the results for this analysis as the lowest and 
highest possible prevented visits associated with a percentage point decrease or increase in 
uptake, respectively. We generated the lowest estimate by combining the 2.5 percentile 
values for MA-RSVi rates, lowest efficacy and uptake, and shortest duration, for each 
product as inputs (Table 2). High estimates were achieved by combining the 97.5 percentile 
values for MA-RSVi rates, highest efficacy and uptake, and longest duration, for each 
product.
3. Results
3.1. Visits without immunization
We estimate, in the absence of palivizumab use, RSV-associated LRTIs in the US among 
infants up to 12 months of age, would result in 407,360 annual outpatient clinic visits (range, 
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based on RSV rates uncertainty: 339,650–475,980); 147,240 annual ED visits (range: 
126,070–168,510), and annual 33,180 hospitalizations (range: 24,760–42,900).
3.2. Visits prevented with immunization
In our illustrative scenario, Strategy II (the “Antibody Candidate”) prevented the most 
annual LRTIs. (Fig. 1) This strategy prevents an estimated 196,470 (48% of visits without 
immunization) RSV-associated LRTIs attended in the outpatient clinic setting (range: 
163,810–229,650), 75,250 (51%) LRTIs attended in the ED (range: 64,430–86,090), and 
18,140 (55%) LRTI hospitalizations (range: 13,770–23,160). Strategy III (the “Maternal 
Vaccine Candidate + Palivizumab”), prevented an estimated 58,210 (14% of visits without 
immunization) RSV-associated LRTIs attended in the outpatient clinic setting (range: 
48,520–67,970), 19,580 (13%) LRTIs attended in the ED (range: 16,760–22,400), and 8190 
(25%) LRTI hospitalizations (range: 6,390–10,150). We estimate that Strategy I, (“Current 
US Recommendations”), prevents 8,460 (2% of visits without immunization) RSV-
associated LRTIs attended in the outpatient clinic setting (range: 7,050–9,880), 3,240 (2%) 
LRTIs attended in the ED (range: 2,770–3,710), and 780 (2%) LRTI hospitalizations (range: 
760–800).
3.3. Deaths with and without immunization
We estimated 33 deaths (range: 25–43) would occur annually among hospitalized infants in 
the US from RSV-associated LRTIs in the absence of immunization, and following current 
recommendations for palivizumab use (Strategy I) prevents just one death. Eighteen in-
hospital deaths (range: 14–23) would be prevented if immunization were implemented 
according to Strategy II, and eight in-hospital deaths (range: 6–10) prevented with Strategy 
III.
3.4. Sensitivity analyses
The relative influence of individual parameters on our estimates of prevented LRTI-
associated visits varied by immunization strategy and healthcare setting. In both Strategies II 
and III, uncertainty in the duration of immunization protection was the most influential 
parameter, except for the hospital setting, where uncertainty in RSV rates was more 
influential in Strategy II (Fig. 2). When results assuming 120 and 180 days of protection by 
the antibody candidate are compared, the estimated LRTI visits prevented differed by 3,080 
in the hospital setting, 26,960 in the ED setting, and 79,070 in the outpatient clinic setting. 
When results assuming 60 and 120 days of protection by the maternal vaccine candidate are 
compared, the estimated LRTI visits prevented differed by 3,880 in the hospital setting, 
20,950 in the ED setting, and 51,840 in the outpatient clinic setting. The more pronounced 
effects of immunization duration in Strategy III results from RSV rates peaking for the 
outpatient and ED setting at ages just after our baseline 90-day duration (Table S1). 
Antibody candidate uptake exhibited the least influence on prevented LRTIs in Strategy II. 
In contrast, efficacy was the least influential parameter in Strategy III.
The results of our multivariable sensitivity analysis suggest changes in the antibody 
candidate uptake have a larger impact in preventing RSV-associated LRTI visits than would 
uptake changes in the maternal vaccine candidate. For every percentage point increase in 
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uptake of the antibody candidate, we estimate 1,435–3,527 outpatient visits would be 
prevented, compared with 273–1,611 for the same increase in the maternal vaccine 
candidate. In the ED setting, a one percentage point increase in antibody candidate uptake is 
associated with 548–1,248 LRTI visits prevented, while the same uptake increase in 
maternal vaccine candidate would prevent between 82 and 588 LRTIs. In the hospital 
setting, a one percentage point increase in antibody candidate uptake is associated with 128 
to 329 prevented LRTIs, and 58 to 215 prevented LRTIs for the maternal vaccine candidate.
4. Discussion
Using the model and our best estimates of the parameters, we found that in the absence of an 
immunization, there are ~590,000 MA-RSV LRTIs among US infants and that new 
interventions that target all infants may prevent between ~86,000 to ~290,000 of those visits. 
These results indicate substantial RSV morbidity and associated healthcare utilization due to 
serious RSVi may be averted with new products under development. Few deaths (8–18), 
however, are averted, since few deaths in the US are attributed to RSVi. Of the candidates 
evaluated, administering an antibody candidate to all infants born during the season and at 
the season’s start for those born outside the season, prevents the most MA-LRTIs. With this 
strategy, we estimate nearly 200,000 outpatient clinic visits, 75,000 ED visits, and 18,000 
hospitalizations for LRTIs could be prevented annually; approximately 48–55% (across 
settings) of visits estimated to occur without immunization. Our baseline estimates suggest 
this strategy may avert approximately 3.5 times the number visits for RSV-associated LRTIs 
to outpatient clinics and EDs, and two times the hospitalizations than a strategy in which a 
maternal vaccine candidate is offered to mothers year-round (in addition to palivizumab use 
per current US recommendations).
In our illustrative scenario, the difference in the number of prevented visits associated with 
candidates was largely attributable to the maternal candidate’s duration of protection being 
less than the antibody candidates’ duration of protection. This was especially pronounced in 
the outpatient clinic and ED settings, where the peak of incidence is beyond the 90 days of 
protection assumed for the maternal candidate. Consequently, changes to our duration 
assumptions for the maternal vaccine candidate had the greatest influence on product 
impact. Despite its lower impact, the maternal vaccine candidate has the potential to reduce 
MA-RSV LRTIs across all three settings by ~74,000 visits a year (beyond the ~12,500 visits 
prevented by palivizumab in our baseline scenario). Preliminary results suggest the efficacy 
of a maternal vaccine may be half what we assumed in our baseline estimates [20]. This 
would reduce visits prevented by the maternal vaccine candidate by about half, but not 
change the overall conclusion about the relative merits of the products and strategies 
evaluated.
Although uncertainty in factors over which public health practitioners have some influence, 
like uptake, had less impact on results, they were not trivial. For example, our multivariable 
sensitivity analysis suggests a 10% increase in uptake of the antibody candidate is associated 
with preventing an additional 14,350 to 35,270 outpatient clinic visits, 5,480–12,480 ED 
visits, and 1,280 to 3,290 hospitalizations for LRTIs. Similarly, a 10% increase in maternal 
vaccine candidate uptake is associated with preventing 2,730–16,110 outpatient clinic visits, 
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820–5,880 ED visits, and 580–2,150 hospitalizations for LRTIs. We also examined the 
influence of the timing of maternal vaccine uptake, by altering the immunization schedule so 
that it optimized the proportion of infants to whom antibodies successfully transfer (S2). The 
difference between these results and our baseline results were negligible.
The relative impact of strategies on hospitalizations are similar to Cromer et al.’s findings 
(ED and outpatients are not comparable) [13]. If we assume 100% uptake for both candidate 
products and limit our evaluation to infants <6 months of age (to match Cromer et al.’s 
analysis) we find the antibody candidate prevents 1.7 times more hospitalizations than the 
maternal vaccine candidate, compared with a ratio of 1.8 in Cromer et al. Our findings are 
also in line with previous studies examining the effect of a single type of vaccine with 
similar characteristics to products we examined. For example, Regnier, using a decision tree 
model to examine a theoretical vaccine for protecting infants in the US from birth, also 
estimated a 25% reduction in hospitalizations, but with assumptions of 69% uptake, 50% 
efficacy, and a decaying exponential distribution for the duration of protection with a 12 
month median length [17]. And Hogan et al., employing a compartmental transmission 
model to examine maternal vaccine impacts in Western Australia, similarly estimated a 25% 
reduction in hospitalizations when assuming a similar immunization scenario of 50% 
uptake, 80% efficacy, and 3 months duration of protection [14]. A strength of our study is its 
simplicity. We focus on the impacts of products on infants who are actually immunized, 
which will be of specific interest to policy-makers developing RSV immunization 
guidelines. We do not estimate the indirect effects of immunization in infants (i.e. secondary 
infections prevented). However, this should not be seen as a limitation. Even Hogan et al. 
concluded from their transmission model that herd effects due to the maternal vaccine were 
modest and a simple cohort model would be a reliable alternative for estimating 
immunization impacts among infants [14]. Additional strengths of our study include 
evaluation of multiple candidate products, the separate consideration of infants with higher 
risk of healthcare use for RSV infection and the additional evaluation of the outpatient and 
emergency department settings.
RSV I2M has limitations. Estimates of immunization impact are restricted to the season in 
which they are given. It is possible that these products will shift the demand for care to 
subsequent seasons, although there is evidence that primary infection with RSV beyond 12 
months of age is less likely to result in an LRTI [21]. We also do not account for the possible 
protection of mothers against RSVi by the maternal vaccine candidate. As such, and because 
we do not account for herd effects, we may underestimate the actual benefit of immunizing 
mothers. Other limitations, however, may result in our overestimation of immunization 
benefits. For example, our assumption that effective immunization averts healthcare use does 
not account for the potential that some portion of immunized infants may still become 
infected with RSV, but require a lower level of care (e.g. shift from hospitalization to 
outpatient visit). We also assumed an additive effect of palivizumab on top of visits 
prevented by the maternal vaccine candidate in Strategy III, on the basis that the population 
of “high-risk” births may derive partial protection from the maternal vaccine and from 
palivizumab. Any overestimation from this limitation, however, is negligible (in the US at 
least), since < 1% of births are affected. For jurisdictions that do not use palivizumab or who 
wish to see the potential impact of the maternal vaccine alone, users can set palivizumab 
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uptake to 0%. It is worth noting that similar flexibility exists for analyzing impacts by 
setting: jurisdictions wishing to evaluate only the hospital setting can just input rates for this 
setting.
4.1. Conclusions
Our model provides decision makers with the ability to examine the impact of directly or 
indirectly immunizing infants against RSV infection with anticipated immunization 
products. As such, local and national public health agencies may use it to evaluate 
jurisdiction-specific scenarios of impact. The findings can be used in economic analyses to 
understand the direct costs and benefits of these strategies and others. The results of our 
illustrative scenario underscore potential for these products to reduce serious RSV illness 
and the benefits of each. Although we found limited impact of these products on deaths 
averted in the United States, they may have greater impact in places where RSV-associated 
deaths are more common. As more data become available regarding immunization 
candidates (i.e. study results regarding efficacy and length of protection) and the burden of 
RSV infections, our tool permits rapid updating of results.
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Fig. 1. 
Estimated number of LRTI Visits Expected without Immunization and Prevented by 
Immunization in the US, by Healthcare Setting and Immunization Strategy. Error bars reflect 
uncertainty in the number of prevented MA-LRTIs associated with uncertainty in RSV rates. 
Uncertainty in the expected visits despite immunization is not shown.
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Fig. 2. 
Sensitivity of Estimates of LRTI Visits Prevented to Select Model Parameters. Top row: 
Immunization Strategy II (the “Antibody Candidate” Strategy). Bottom row: Immunization 
Strategy III (the “Maternal Vaccine Candidate + Palivizumab” Strategy). Parameter values 
not shown, provided in Table 2.
Rainisch et al. Page 13
Vaccine. Author manuscript; available in PMC 2020 February 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rainisch et al. Page 14
Ta
bl
e 
1
Im
m
un
iz
at
io
n 
St
ra
te
gi
es
. Str
at
eg
y 
I
St
ra
te
gy
 II
St
ra
te
gy
 II
I
Im
m
un
iz
at
io
n 
Pr
o
du
ct
s
Pa
liv
iz
um
ab
 (li
ce
ns
ed
)
A
nt
ib
od
y 
C
an
di
da
te
M
at
er
n
a
l V
a
cc
in
e 
C
an
di
da
te
Pa
liv
iz
um
ab
 (li
ce
ns
ed
)
El
ig
ib
ili
ty
H
ig
h-
ris
k 
in
fa
n
ts
*
A
ll 
in
fa
n
ts
A
ll 
pr
eg
na
nt
 w
o
m
en
¶
H
ig
h-
ris
k 
in
fa
n
ts
*
W
he
n 
of
fe
re
d
W
ith
in
-R
SV
 se
as
on
W
ith
in
-R
SV
 se
as
on
Ye
ar
-
ro
u
n
d
W
ith
in
-R
SV
 se
as
on
A
dm
in
ist
ra
tio
n 
Sc
he
du
le
M
on
th
ly
 in
jec
tio
ns 
for
 5 
mo
nth
s
Si
ng
le
 in
jec
tio
n
Si
ng
le
 in
jec
tio
n
M
on
th
ly
 in
jec
tio
ns 
for
 5 
mo
nth
s
A
ge
 w
he
n 
im
m
un
iz
at
io
n 
in
iti
at
ed
W
ith
in
-s
ea
so
n 
bi
rth
: a
t b
irt
h 
O
ut
-o
f-s
ea
so
n 
bi
rth
: a
ge
 a
t s
ea
so
n’
s s
ta
rt 
(1–
6 m
on
ths
)
W
ith
in
-s
ea
so
n 
bi
rth
: a
t b
irt
h 
O
ut
-o
f-
se
as
o
n
 b
irt
h:
 a
ge
 a
t s
ea
so
n’
s s
ta
rt 
(1–
6 
m
o
n
th
s)
3r
d 
tri
m
es
te
r o
f m
ot
he
r’s
 
pr
eg
na
nc
y
W
ith
in
-s
ea
so
n 
bi
rth
: a
t b
irt
h 
O
ut
-o
f-s
ea
so
n 
bi
rth
: a
ge
 a
t s
ea
so
n’
s s
ta
rt 
(1–
6 m
on
ths
)
*
H
ig
h 
ris
k 
co
nd
iti
on
s i
nc
lu
de
 h
em
od
yn
am
ic
al
ly
 si
gn
ifi
ca
nt
 c
on
ge
ni
ta
l h
ea
rt 
di
se
as
e 
(C
HD
), c
hro
nic
 lu
ng
 di
sea
se 
of 
pre
ma
tur
ity
 (C
LD
), a
nd
 pr
em
atu
rit
y (
<2
9 w
ee
ks
 ge
sta
tio
n) 
wi
tho
ut 
CH
D 
or 
CL
D.
¶ R
isk
 st
at
us
 o
f i
nf
an
t i
s n
ot
 k
no
w
n
 a
t t
im
e 
of
 im
m
un
iz
at
io
n.
Vaccine. Author manuscript; available in PMC 2020 February 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rainisch et al. Page 15
Ta
bl
e 
2
In
pu
ts 
an
d 
Pa
ra
m
et
er
 V
al
ue
s f
or
 A
ll 
Sc
en
ar
io
s o
f P
ro
du
ct
 Im
pa
ct
s i
n 
th
e 
U
S.
Pa
ra
m
et
er
Ba
se
lin
e 
Va
lu
e
R
an
ge
 (u
sed
 in
 se
ns
iti
v
ity
 a
na
ly
se
s)
U
se
r-
a
dju
sta
ble
So
ur
ce
Po
pu
la
tio
n 
an
d 
Ep
id
em
io
lo
gi
ca
l
A
nn
ua
l l
iv
e 
bi
rth
s
3,
94
5,
97
5
Ye
s
[2
2]
B
irt
hs
 w
ith
 c
on
di
tio
ns
 p
ut
tin
g 
th
em
 a
t “
hi
gh
-R
SV
 ri
sk
”§
0.
98
%
Ye
s
[2
3]
Pe
rc
en
t o
f “
hi
gh
-ri
sk
” 
ho
sp
ita
liz
ed
 b
ef
or
e 
12
 m
on
th
s
9.
31
%
Ye
s
Ca
lc
ul
at
ed
, S
2
R
at
es
 o
f M
ed
ic
al
ly
-A
tte
nd
ed
 R
SV
 (p
er 
10
00
 bi
rth
s)
Ye
s
Se
e 
S2
 fo
r d
at
a
 
H
os
pi
ta
liz
at
io
ns
8.
4
(1.
5–
30
.8)
ta
bl
es
/so
ur
ce
s
 
Em
er
ge
nc
y 
D
ep
ar
tm
en
t (
ED
) V
isi
ts
66
.2
(16
.8–
13
2.7
)
 
O
ut
pa
tie
nt
 C
lin
ic
 V
isi
ts
23
0.
9
(71
.0–
33
7.2
)
Pr
op
or
tio
n 
of
 M
A
-R
SV
i v
isi
ts 
w
ith
 a
n 
LR
TI
 d
ia
gn
os
is,
 b
y 
0–
5/
5–
11
 m
on
th
s o
f a
ge
 ca
te
go
rie
s^
Ye
s
CD
C/
un
pu
bl
ish
ed
 
H
os
pi
ta
liz
at
io
ns
1.
00
/1
.0
0
 
ED
 V
isi
ts
0.
65
/0
.5
0
 
O
ut
pa
tie
nt
 C
lin
ic
 V
isi
ts
0.
65
/0
.3
0
Ca
se
 fa
ta
lit
y 
ra
tio
s†
Ye
s
[1
]
 
0–
5 
m
on
th
s (
%)
0.
10
 
5–
11
 m
on
th
s (
%)
0.
10
R
SV
 se
as
on
O
ct
ob
er
-
M
ar
ch
Ye
s
CD
C/
un
pu
bl
ish
ed
; S
2
Im
m
un
iz
at
io
n
U
pt
ak
e#
 
Pa
liv
iz
um
ab
38
.0
%
Ye
s
[2
4,
25
]
 
A
nt
ib
od
y 
Ca
nd
id
at
e
 
 
Lo
w
-r
isk
71
%
(66
–7
6)
Ye
s
A
ss
um
ed
, [
26
,
27
]*
*
 
 
H
ig
h-
ris
k
80
%
Ye
s
A
ss
um
ed
, [
23
]¶¶
 
M
at
er
na
l V
ac
ci
ne
 C
an
di
da
te
56
%
(51
–6
1)
Ye
s
A
ss
um
ed
, [
28
]‡‡
A
nt
ib
od
ie
s p
ro
po
rti
on
 su
cc
es
sf
ul
ly
 tr
an
sf
er
re
d 
to
 in
fa
n
ts
91
.9
%
Ye
s
Ca
lc
ul
at
ed
, S
2
Ef
fic
ac
y 
(as
so
cia
ted
 w
ith
 fu
ll i
mm
un
iza
tio
n d
os
ag
e)
 
 
Pa
liv
iz
um
ab
51
%
Ye
s
[2
9]
§§
Vaccine. Author manuscript; available in PMC 2020 February 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rainisch et al. Page 16
Pa
ra
m
et
er
Ba
se
lin
e 
Va
lu
e
R
an
ge
 (u
sed
 in
 se
ns
iti
v
ity
 a
na
ly
se
s)
U
se
r-
a
dju
sta
ble
So
ur
ce
 
 
A
nt
ib
od
y 
Ca
nd
id
at
e
80
%
(73
–8
5)
Ye
s
A
ss
um
ed
, [
30
]^^
 
 
M
at
er
na
l V
ac
ci
ne
 C
an
di
da
te
80
%
(73
–8
5)
Ye
s
A
ss
um
ed
, [
30
]^^
D
ur
at
io
n 
of
 P
ro
te
ct
io
n
 
 
Pa
liv
iz
um
ab
15
0 
da
ys
N
o
[3
1,
32
]
 
 
A
nt
ib
od
y 
Ca
nd
id
at
e
15
0 
da
ys
(12
0–
18
0)
Ye
s
[1
0]
 
 
M
at
er
na
l V
ac
ci
ne
 C
an
di
da
te
90
 d
ay
s
(60
–1
20
)
Ye
s
[1
1]
¶ Il
lu
str
at
iv
e 
av
er
ag
e 
(un
ad
jus
ted
) p
op
ula
tio
n r
ate
s. S
2 c
on
tai
ns 
the
 ac
tua
l a
ge
-ba
sed
 (m
on
thl
y) 
rat
es 
use
d i
n a
ll a
na
lys
es.
§ H
ig
h 
ris
k 
co
nd
iti
on
s i
nc
lu
de
 h
em
od
yn
am
ic
al
ly
 si
gn
ifi
ca
nt
 C
on
ge
ni
ta
l H
ea
rt 
D
ise
as
e 
(C
HD
), C
hro
nic
 L
un
g D
ise
ase
 of
 Pr
em
atu
rit
y (
CL
D)
, a
nd
 Pr
em
atu
rit
y (
<2
9 w
ee
ks
 ge
sta
tio
n) 
wi
tho
ut 
CH
D 
or 
CL
D.
^
B
as
ed
 o
n 
th
e 
av
er
ag
e 
of
 n
um
be
r o
f l
ab
-c
on
fir
m
ed
 R
SV
 v
isi
ts 
fro
m
 a
 n
at
io
na
l s
ur
ve
ill
an
ce
 sy
ste
m
 b
et
w
ee
n 
20
02
 a
nd
 2
00
9 
w
ith
 an
y 
of
 th
e 
fo
llo
w
in
g 
di
ag
no
se
s: 
cr
ou
p,
 b
ro
nc
hi
ol
iti
s, 
br
on
ch
iti
s, 
pn
eu
m
on
ia
 
o
r 
as
th
m
a.
† B
as
ed
 o
n 
es
tim
at
es
 fo
r “
hi
gh
 in
co
m
e/
in
du
str
ia
liz
ed
” 
co
un
tri
es
.
# P
er
ce
nt
 o
f e
lig
ib
le
 p
op
ul
at
io
n 
ta
rg
et
ed
 to
 re
ce
iv
e 
an
 im
m
un
iz
at
io
n 
pr
od
uc
t t
ha
t a
ct
ua
lly
 o
bt
ai
ns
 a
nd
 c
om
pl
et
es
 th
e 
fu
ll 
re
gi
m
en
. F
o
r 
Pa
liv
iz
um
ab
: O
ne
 in
jec
tio
n m
on
thl
y f
or 
5 m
on
ths
 on
 tim
e. 
Fo
r 
A
nt
ib
od
y 
&
 M
at
er
na
l V
ac
ci
ne
 C
an
di
da
te
s: 
O
ne
 in
jec
tio
n.
*
*
B
as
el
in
e 
va
lu
e 
is 
ba
se
d 
on
 si
m
ila
r u
pt
ak
es
 fo
r H
ep
at
iti
s B
 v
ac
ci
ne
 in
 n
eo
na
te
s [
27
] (
ap
pli
ca
ble
 to
 bi
rth
s w
ith
in 
the
 R
SV
 se
aso
n) 
an
d I
nfl
ue
nz
a i
mm
un
iza
tio
n c
ov
er
ag
e 
am
on
g 
6 
m
on
th
 to
 4
 y
ea
r o
ld
s [
26
] 
(ap
pli
ca
ble
 to
 bi
rth
s o
cc
urr
ing
 ou
tsi
de
 R
SV
 se
aso
n).
 R
an
ge
 is
 −/
+ 5
 of
 ba
sel
ine
 in
 th
e a
bs
en
ce
 of
 da
ta.
¶¶
B
as
ed
 o
n 
th
e 
pe
rc
en
t o
f b
irt
hs
 th
at
 o
bt
ai
ne
d 
th
e 
1s
t p
al
iv
iz
um
ab
 in
jec
tio
n [
23
].
‡‡
B
as
el
in
e 
ba
se
d 
on
 av
er
ag
e 
Td
aP
 (t
eta
nu
s, 
dip
hth
eri
a, 
pe
rtu
ssi
s) 
up
tak
e 
am
o
n
g 
pr
eg
na
nt
 w
o
m
en
 d
ur
in
g 
a 
15
 m
on
th
 st
ud
y 
pe
rio
d 
fro
m
 A
pr
il 
20
13
 - 
Ju
ne
 2
01
4 
[2
8]
; a
nd
 ra
ng
e i
s −
/+
 5 
of
 ba
se
lin
e. 
Td
aP
,
 
lik
e 
th
e 
m
at
er
na
l R
SV
 v
ac
ci
ne
, i
s g
iv
en
 in
 th
e 
3r
d 
tri
m
es
te
r o
f p
re
gn
an
cy
.
§§
Th
is 
is 
th
e 
ef
fic
ac
y 
as
so
ci
at
ed
 w
ith
 o
ur
 a
ss
um
ed
 u
pt
ak
e 
(i.
e. 
co
mp
lia
nc
e w
ith
 al
l d
os
es)
 [2
9]
.
^
^
B
as
ed
 o
n 
av
er
ag
e 
ef
fic
ac
y 
fo
r t
er
m
 in
fa
n
ts
 a
cr
os
s 
al
l h
ea
lth
ca
re
 se
tti
ng
s (
ho
sp
ita
liz
ati
on
s, 
ED
, a
nd
 ou
tpa
tie
nt 
cli
nic
s) 
in 
a s
tud
y e
x
am
in
in
g 
th
e 
ef
fic
ac
y 
of
 m
ot
av
iz
um
ab
 a
nd
 o
ur
 a
ss
um
pt
io
n 
of
 si
m
ila
rit
y 
be
tw
ee
n 
it 
an
d 
th
is 
stu
dy
’s
 a
nt
ib
od
y 
an
d 
m
at
er
na
l v
ac
ci
ne
 c
an
di
da
te
s [
30
].
Vaccine. Author manuscript; available in PMC 2020 February 19.
